Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
Holding NTLA?
Track your performance easily
NTLA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.95 - $34.87
Previous Close$17.5
Volume2.64M
Average Volume (3M)1.92M
Market Cap
$1.78B
Enterprise Value$1.23B
Total Cash (Recent Filing)$658.11M
Total Debt (Recent Filing)$101.62M
Price to Earnings (P/E)―
Beta2.93
Next Earnings
Feb 20, 2025EPS Estimate
-$1.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.45
Shares Outstanding101,848,572
10 Day Avg. Volume2,820,166
30 Day Avg. Volume1,922,936
Standard Deviation0.25
R-Squared0.15
Alpha0.00493
Financial Highlights & Ratios
Price to Book (P/B)1.85
Price to Sales (P/S)39.44
Price to Cash Flow (P/CF)-5.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue28.45
Enterprise Value/Gross Profit33.79
Enterprise Value/Ebitda-2.48
Forecast
1Y Price Target
$55.68Price Target Upside234.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
Intellia Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsEnrollment in the pivotal Phase 3 MAGNITUDE trial of NTLA-2001 in patients with ATTR-CM continues to track ahead of schedule.
Financial PerformanceIntellia had $944.7M in cash which should fund operations into late-2026.
Regulatory ProgressFDA clearance ensures that the FDA is in alignment with trial design, which bodes well for the eventual BLA filing.
Bears Say
Efficacy ConcernsIn recent trials, the 6-minute walk distance declined by approximately 19-24 meters in the treated group, showing no meaningful difference compared to placebo.
Market CompetitionThe availability of competing HAE treatments with similar efficacy profiles is expected to be a substantial challenge for the NTLA-2002 program.
Stock Dilution RiskThe continued use of the ATM program to raise funds could result in a near-term headwind for shares.
---
Ownership Overview
1.74% Insiders
21.73% Mutual Funds
21.24% Other Institutional Investors
24.51% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NTLA FAQ
What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest stock price was $13.95 and its highest was $34.87 in the past 12 months.
What is Intellia Therapeutics’s market cap?
Currently, no data Available
When is Intellia Therapeutics’s upcoming earnings report date?
Intellia Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is in 99 days.
How were Intellia Therapeutics’s earnings last quarter?
Intellia Therapeutics released its earnings results on Nov 07, 2024. The company reported -$1.34 earnings per share for the quarter, beating the consensus estimate of -$1.39 by $0.05.
Is Intellia Therapeutics overvalued?
According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued.
Does Intellia Therapeutics pay dividends?
Intellia Therapeutics does not currently pay dividends.
What is Intellia Therapeutics’s EPS estimate?
Intellia Therapeutics’s EPS estimate is -$1.35.
How many shares outstanding does Intellia Therapeutics have?
Intellia Therapeutics has 101,848,570 shares outstanding.
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Intellia Therapeutics reported an EPS of -$1.34 in its last earnings report, beating expectations of -$1.39. Following the earnings report the stock price went down -0.374%.
Which hedge fund is a major shareholder of Intellia Therapeutics?
Among the largest hedge funds holding Intellia Therapeutics’s share is ARK Investment Management LLC. It holds Intellia Therapeutics’s shares valued at 260M.
---
Intellia Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.68 (234.41% Upside)
$55.68 (234.41% Upside)
Blogger Sentiment
Bullish
NTLA Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 613.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $38.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 7.0%
Last 30 Days ▲ 7.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.47%
12-Months-Change
Fundamentals
Return on Equity
-52.23%
Trailing 12-Months
Asset Growth
-5.63%
Trailing 12-Months
Company Description
Intellia Therapeutics
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
---
NTLA Earnings Call
Q3 2024
0:00 / 0:00
---
NTLA Revenue Breakdown
100.00% Collaboration revenue
---
NTLA Stock 12 Month Forecast
Average Price Target
$55.68
▲(234.41% Upside)
Technical Analysis
Editas Medicine
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Arcturus Therapeutics
―
Best Analysts Covering NTLA
1 Year
1 Year Success Rate
15/38 ratings generated profit
1 Year Average Return
+89.63%
reiterated a buy rating 6 days ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 39.47% of your transactions generating a profit, with an average return of +89.63% per trade.
---